Paradigm’s 5000x average depth of coverage ensures confidence in that both positive and negative calls are correct. This type of assurance cannot be achieved at lower levels.
Through next-generation sequencing, PCDx assesses the most clinically-actionable genomic variations in cancer, including: mutations, gene fusions, mRNA expression, and copy number variations.
Paradigm promises a clinically relevant turnaround time. Customers can expect 4 to 5 business days from sample receipt to reporting ensures continuity of clinical care.
CNVs are alterations of the DNA of the cancer genome that result in the cell having abnormal copies of one or more sections of the DNA. These alterations can have a significant impact on response to therapy (e.g., HER2).
Gene expression is the process by which information from a gene is used in the synthesis of a functional protein. NGS-based mRNA analysis enables the significant multiplexing of biomarker targets (e.g., ER, ERCC1).
Somatic rearrangements usually result in the formation of a fusion gene, derived from two disrupted normal genes, from which a fusion transcript and protein is generated (e.g., EML4-ALK).
Changes in the DNA sequence of chromosomes, including insertions, deletions and base substitutions. Somatic mutation analysis has become standard of practice for solid tumors in order to identify therapeutic sensitizing and resistance mutations (e.g., EGFR, KRAS, BRAF).
Sample is received and pathology confirms initial diagnosis with H&E.
Tumor DNA & RNA are extracted, purified and quantified.
DNA & RNA library creation.
Clinical interpretation of results, quality assurance performed and clinical report delivered.
The PDF test requisition form can be completed digitally, within Adobe Acrobat.Download the form
For your convenience, the requisition form can be sent to Paradigm via email or fax.View ordering information
Please follow our preparation & shipping guidelines to ensure quality DNA/RNA analysis.View tissue prep guidelines
Results will identify all actionable classes of genomic alterations in cancer-related genes.Learn about PCDx